trending Market Intelligence /marketintelligence/en/news-insights/trending/X_e6EuRnnsyrk8V9cC7bfQ2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

VistaGen's nasal spray wins US FDA fast-track designation for anxiety disorder

Blog

Needham & Company is Now Available in the S&P Global Market Intelligence Aftermarket Research Collection

Blog

Banking Essentials Newsletter - February Edition

Blog

Message in a (Word)Cloud

Six trends shaping the industries and sectors we cover in 2021


VistaGen's nasal spray wins US FDA fast-track designation for anxiety disorder

The U.S. Food and Drug Administration granted the fast-track designation to VistaGen Therapeutics Inc.'s nasal spray PH94B.

SNL Image

The company was evaluating PH94B as a treatment that is nonaddictive, nonsedating and can be taken as and when needed, VistaGen said, adding that the company is preparing for PH94B's phase 3 trials. The South San Francisco, Calif.-based biopharmaceutical company's treatment is aimed at treating social anxiety disorder.

Fast-track designation gives regulatory priority to treatments that show promise, including frequent meetings with the FDA and priority review of the marketing application.

VistaGen also has a depression medicine, called AV-101, which has failed two mid-stage studies.